Divis Laboratories provides update on USFDA inspection of Visakhapatnam unit
Files detailed response to Form 483 observations
Divis Laboratories announced that its has filed its detailed response to the 'Form 483' observations of the US-FDA for the Company's unit at Visakhapatnam within the time permitted.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content